Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021:1303:89-105.
doi: 10.1007/978-3-030-63046-1_6.

MicroRNA Targets for Asthma Therapy

Sabrina C Ramelli  1 , William T Gerthoffer  2
Affiliations

MicroRNA Targets for Asthma Therapy

Sabrina C Ramelli et al. Adv Exp Med Biol. 2021.

Abstract

Asthma is a chronic inflammatory obstructive lung disease that is stratified into endotypes. Th2 high asthma is due to an imbalance of Th1/Th2 signaling leading to abnormally high levels of Th2 cytokines, IL-4, IL-5, and IL-13 and in some cases a reduction in type I interferons. Some asthmatics express Th2 low, Th1/Th17 high phenotypes with or without eosinophilia. Most asthmatics with Th2 high phenotype respond to beta-adrenergic agonists, muscarinic antagonists, and inhaled corticosteroids. However, 5-10% of asthmatics are not well controlled by these therapies despite significant advances in lung immunology and the pathogenesis of severe asthma. This problem is being addressed by developing novel classes of anti-inflammatory agents. Numerous studies have established efficacy of targeting pro-inflammatory microRNAs in mouse models of mild/moderate and severe asthma. Current approaches employ microRNA mimics and antagonists designed for use in vivo. Chemically modified oligonucleotides have enhanced stability in blood, increased cell permeability, and optimized target specificity. Delivery to lung tissue limits clinical applications, but it is a tractable problem. Future studies need to define the most effective microRNA targets and effective delivery systems. Successful oligonucleotide drug candidates must have adequate lung cell uptake, high target specificity, and efficacy with tolerable off-target effects.

Keywords: Antisense; Asthma; House dust mite; LNA; MicroRNA; Oligonucleotide; Ovalbumin; RNAi; Therapy.

PubMed Disclaimer

References

    1. Fahy JV. Type 2 inflammation in asthma--present in most, absent in many. Nat Rev Immunol. 2015;15(1):57–65. https://doi.org/10.1038/nri3786 . - DOI - PubMed - PMC
    1. Levy BD, Noel PJ, Freemer MM, Cloutier MM, Georas SN, Jarjour NN, Ober C, Woodruff PG, Barnes KC, Bender BG, Camargo CA Jr, Chupp GL, Denlinger LC, Fahy JV, Fitzpatrick AM, Fuhlbrigge A, Gaston BM, Hartert TV, Kolls JK, Lynch SV, Moore WC, Morgan WJ, Nadeau KC, Ownby DR, Solway J, Szefler SJ, Wenzel SE, Wright RJ, Smith RA, Erzurum SC. Future research directions in asthma. An NHLBI Working Group report. Am J Respir Crit Care Med. 2015;192(11):1366–72. https://doi.org/10.1164/rccm.201505-0963WS . - DOI - PubMed - PMC
    1. Mersha TB, Afanador Y, Johansson E, Proper SP, Bernstein JA, Rothenberg ME, Khurana Hershey GK. Resolving clinical phenotypes into endotypes in allergy: molecular and omics approaches. Clin Rev Allergy Immunol. 2020; https://doi.org/10.1007/s12016-020-08787-5 .
    1. Wenzel S. Severe/fatal asthma. Chest. 2003;123(3 Suppl):405S–10S. https://doi.org/10.1378/chest.123.3_suppl.405s-a . - DOI - PubMed
    1. Trevor JL, Deshane JS. Refractory asthma: mechanisms, targets, and therapy. Allergy. 2014;69(7):817–27. https://doi.org/10.1111/all.12412 . - DOI - PubMed - PMC

LinkOut - more resources